By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Accentia, Inc. 

5310 Cypress Center Drive #101

Tampa  Florida  33609  U.S.A.
Phone: 813-864-2554 Fax: 813-287-6642


Company News
Accentia, Inc., Biovest International, Inc. Emerges from Chapter 11 Reorganization 11/17/2010 6:57:55 AM
Accentia, Inc. Files Plan of Reorganization; Restructuring Supports Plans to Advance Promising Multiple Sclerosis Therapy into Late-Stage Clinical Trial 6/1/2010 6:29:18 AM
Accentia, Inc.'s CEO Provides Outlook for 2008 including Update on SinuNase Phase 3 Blinded Trial Results on 80% of Patients 1/7/2008 8:31:22 AM
Accentia, Inc. Announces Investigational New Drug Application for Revimmune Usage in a Pivotal Phase 3 Study of Refractory Multiple Sclerosis 10/8/2007 8:09:34 AM
Accentia, Inc. Says Interim Data on SinuNase Promising 6/28/2007 10:05:38 AM
FDA Gives Permission To Use Very Sensitive Molecular Evidence Of Cancer In BiovaxID Pivotal Phase 3: Company Intends To Use Blood Test To File Application For Accelerated Approval 5/16/2006 12:53:14 PM
Accentia, Inc. Says Cancer Vaccine Raises Survival, Shares Up 1/24/2006 10:23:51 AM
Accentia Biopharmaceuticals Licenses Targeted Technology For Treatment Of Chronic Rhinosinusitis (CRS): 37 Million Affected In The US And No Approved Pharmaceutical10/19/2005 5:10:54 PM
BioDelivery Sciences International (BDSI) Announces $2,500,000 Asset Sale To Accentia, Inc.10/19/2005 5:10:19 PM
PPD, Inc. (PPDI) Makes Equity Investment In Accentia, Inc.10/19/2005 5:09:55 PM